Fennec Pharmaceuticals In... (FENC)
Fennec Pharmaceuticals Statistics
Share Statistics
Fennec Pharmaceuticals has 27.43M shares outstanding. The number of shares has increased by 1.43% in one year.
| Shares Outstanding | 27.43M |
| Shares Change (YoY) | 1.43% |
| Shares Change (QoQ) | 0.25% |
| Owned by Institutions (%) | 54.55% |
| Shares Floating | 22.91M |
| Failed to Deliver (FTD) Shares | 500 |
| FTD / Avg. Volume | 0.64% |
Short Selling Information
The latest short interest is 2M, so 7.28% of the outstanding shares have been sold short.
| Short Interest | 2M |
| Short % of Shares Out | 7.28% |
| Short % of Float | 8.72% |
| Short Ratio (days to cover) | 25.61 |
Valuation Ratios
The PE ratio is -18.58 and the forward PE ratio is -41.27. Fennec Pharmaceuticals's PEG ratio is 0.5.
| PE Ratio | -18.58 |
| Forward PE | -41.27 |
| PS Ratio | 14.03 |
| Forward PS | 1.7 |
| PB Ratio | -25.65 |
| P/FCF Ratio | -17.39 |
| PEG Ratio | 0.5 |
Enterprise Valuation
Fennec Pharmaceuticals Inc. has an Enterprise Value (EV) of 314.54M.
| EV / Earnings | -19.6 |
| EV / Sales | 14.8 |
| EV / EBITDA | -25.44 |
| EV / EBIT | -24.63 |
| EV / FCF | -18.35 |
Financial Position
The company has a current ratio of 3.56, with a Debt / Equity ratio of -2.66.
| Current Ratio | 3.56 |
| Quick Ratio | 3.27 |
| Debt / Equity | -2.66 |
| Total Debt / Capitalization | 160.12 |
| Cash Flow / Debt | -0.55 |
| Interest Coverage | -3.76 |
Financial Efficiency
Return on equity (ROE) is 1.38% and return on capital (ROIC) is -66.06%.
| Return on Equity (ROE) | 1.38% |
| Return on Assets (ROA) | -0.6% |
| Return on Capital (ROIC) | -66.06% |
| Revenue Per Employee | $732,827.59 |
| Profits Per Employee | $-553,275.86 |
| Employee Count | 29 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 0.58 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -28.72% in the last 52 weeks. The beta is 0.34, so Fennec Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.34 |
| 52-Week Price Change | -28.72% |
| 50-Day Moving Average | 6.31 |
| 200-Day Moving Average | 5.87 |
| Relative Strength Index (RSI) | 68.62 |
| Average Volume (20 Days) | 78.59K |
Income Statement
In the last 12 months, Fennec Pharmaceuticals had revenue of 21.25M and earned -16.05M in profits. Earnings per share was -0.6.
| Revenue | 21.25M |
| Gross Profit | 19.99M |
| Operating Income | -12.77M |
| Net Income | -16.05M |
| EBITDA | -12.36M |
| EBIT | -12.77M |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has 13.27M in cash and 30.95M in debt, giving a net cash position of -17.68M.
| Cash & Cash Equivalents | 13.27M |
| Total Debt | 30.95M |
| Net Cash | -17.68M |
| Retained Earnings | -219.25M |
| Total Assets | 58.92M |
| Working Capital | 50.53M |
Cash Flow
In the last 12 months, operating cash flow was -17.14M and capital expenditures 2.75, giving a free cash flow of -17.14M.
| Operating Cash Flow | -17.14M |
| Capital Expenditures | 2.75 |
| Free Cash Flow | -17.14M |
| FCF Per Share | -0.65 |
Margins
Gross margin is 94.08%, with operating and profit margins of -60.09% and -75.5%.
| Gross Margin | 94.08% |
| Operating Margin | -60.09% |
| Pretax Margin | -75.5% |
| Profit Margin | -75.5% |
| EBITDA Margin | -58.18% |
| EBIT Margin | -60.09% |
| FCF Margin | -80.67% |
Dividends & Yields
FENC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.57% |
| FCF Yield | -8.93% |
Analyst Forecast
The average price target for FENC is $14, which is 100% higher than the current price. The consensus rating is "Buy".
| Price Target | $14 |
| Price Target Difference | 100% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Sep 9, 2014. It was a backward split with a ratio of 1:3.
| Last Split Date | Sep 9, 2014 |
| Split Type | backward |
| Split Ratio | 1:3 |
Scores
| Altman Z-Score | -1.42 |
| Piotroski F-Score | 4 |